Proven Efficacy
of the Biolimus A9™ Drug
Proven Efficacy
of the Biolimus A9™ Drug
| 1. | Data on file at Biosensors International |
| 8. | Windecker, S. et al., Biolimus-eluting stent with biodegradable polymer versus Sirolimus-eluting stent with durable polymer for coronary revascularization (LEADERS): a randomised non inferiority trial; The Lancet 2008; 372 No. 9644: 1163-1173 |
| 9. | Windecker, S. et al., NEJM 2005; Morice, M.-C. et al., JAMA 2006; Serruys, P.W. et al., EuroIntervention 2006; Stone, G.W. et al., JAMA 2008; Costa, M. et al., Am J Card 2006; Chevalier, B. et al., EuroIntervention 2006; Ostojic, M. et al., EuroIntervention 2008; Stone, G.W. et al., NEJM 2004; Krukoff, M.W., JACC 2008; Verheye, S. et al., ACC/SCAI 2008 |
| The BioMatrix Flex™ stent is indicated in diabetics, STEMI and ACS patients for stents lengths up to 28 mm. | |
CAUTION: The law restricts these devices to sale by or on the order of a physician. Prior to use, it is important to read the "Instructions for Use" supplied with these devices for indications, contraindications, suggested procedures, warnings, and precautions.
Biosensors’ interventional cardiology products, including BioMatrix Flex™, BioMatrix™, Axxess™, BioFreedom™, Gazelle™, Juno™, S-Stent™, Powerline™, Quadrature Link™ and MultiPleat™, are not available for sale in the United States and certain other countries. BioFreedom™ is an investigational device. All other trademarks are the property of their respective owners.
BioMatrix Flex, BioMatrix, Axxess, BioFreedom, Gazelle, Juno, S-Stent, Powerline, Quadrature Link and MultiPleat are trademarks or registered trademarks of Biosensors International Group, Ltd. in the United States and certain other countries. All cited trademarks are the property of their respective owners.
Watch the working principle of our BioMatrix Flex™ abluminal biodegradable polymer DES



